Aktuellt
SENASTE
Redeye updates its estimates following Surgical Science’s Q3 2023 report, which featured considerably lower-than-expected sales. EBITDA and EBIT margins exceeded our estimates by c3%-points. We judge growth will recover in 2024e and nudge down our valuation.
LÄS MER
